Farmas USA

Las llevo a 4,45/ 4,8/ 5,10

He comprado de mas a menos para ir promediando.

OPHT

OPHT a ver si tiramos rápido para arriba que por gráfico pinto bien desde que parece que hizo suelo en 4.27

NVAX, parece que las esperadas news en Enero nanaidelachina

Zika update from IR
Thank you for your interest in Novavax. An update on all of our programs, including our Zika program, will be available as part of our earnings call in February.

Novavax is currently conducting preclinical and IND-enabling studies of our Zika vaccine candidate with the goal of initiating a Phase 1 trial this year.

Best,
Novavax
Investor Relations
[email protected]

Patwin. Tienes datos del pipeline de RGLS en q1 y más en qen q3. Tendrás ocasión de salir en even
Wedbush lowered its price target on Regulus Therapeutics (NASDAQ: RGLS) to $8.00 (from $13.00) while maintaining a Outperform rating after the FDA requested additional safety data from preclinical experiments and an ongoing trial extends the RG-101 / HCV clinical hold into Q1 2018

Liana Moussatos commented. "... we now anticipate the clinical hold could be lifted in Q1 2018 at the earliest and we have delayed our RG-101 / HCV launch estimate by one year to 2023. However, because Regulus previously indicated that they will not release any RG-101 clinical results during the clinical hold including those from the ongoing GSK combo trial, we have removed our value for RG-101 from our price target as no catalysts for that program are now anticipated in 2017."

Meanwhile, the analyst sees progress with multiple other pipeline candidates in 2017. "We believe Regulus is no longer dependent on RG-101 as there are multiple clinical candidates that are either planned or currently active in the clinic in 2017. Pipeline progress in H1 includes Phase 1 multiple ascending dose (MAD) results for RG-012 in healthy volunteers and potential proof-of-concept (PoC) data for RG-125 for T2D/NASH (partner AstraZeneca runs clinical program). In addition, in H2 the Phase 2 HERA study for RG-012/Alport Syndrome is anticipated to resume, two IND filings are anticipated for RGLS5040 for cholestatic diseases and RGLS4326 for ADPKD, and nomination of at least one other clinical candidate."

RGLS
Fuera a 1,35 -1500$.
Poca alegría me ha durado los pluses de ADXS.
Se acabaron los chicharros.

Deje orden de venta en 1,35 se acaba de ejecutar.
Veré como se desarrolla y si vuelve a bajar a 1 o 1,05 comprare unas cuantas a ver si me devuelve algo.

RGLS,,yo acabo de comprar a 1,32.

FGEN

No la sigo, pero y ese -6%? no había sacado buenas noticias?